Biohit Oyj

Equities

BIOBV

FI0009005482

Office Equipment

Delayed Nasdaq Helsinki 11:06:48 2024-03-28 am EDT 5-day change 1st Jan Change
2 EUR +2.04% Intraday chart for Biohit Oyj +3.90% +6.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Biohit Names New Chief Commercial Officer MT
Biohit Oyj Provides Earnings Guidance for the Period from 2024 to 2028 CI
Biohit Oyj Announces Changes in the Management Group CI
Biohit Revises Earnings Guidance for 2023 CI
Biohit Oyj Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Biohit Oyj Elects Vesa Silaskivi as Chairman of the Board of Directors CI
Biohit Oyj Approves Election of Vesa Silaskivi as Members of Board of Directors CI
Biohit Oyj Provides Earnings Guidance for the Year 2023 CI
Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Biohit Oyj Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Biohit Oyj Announces Executive Changes CI
Biohit Appoints New CFO MT
Biohit Oyj Appoints Jussi Sorvo as Chief Financial Officer, Effective on September 7, 2022 CI
Biohit Oyj Appoints Jussi Sorvo as Member of the Management, Effective on September 7, 2022 CI
Finnish Biotech Biohit Appoints CFO as CEO MT
Biohit Oyj Announces Executive Changes CI
Biohit Oyj Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Biohit Oyj Revises Earnings Guidance for the Year 2022 CI
Biohit Oyj Appoints Lea Paloheimo as the Chairman of the Board of Directors CI
Biohit Oyj Elects Kalle Härkönen as Board of Director CI
Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Biohit Oyj Provides Earnings Guidance for the Year 2022 CI
Biohit Oyj Specifies Financial Guidance for 2021 CI
Biohit's GastroPanel Test Backed by Oulu University Hospital Clinical Study MT
Chart Biohit Oyj
More charts
Biohit Oyj is a Finland-based company engaged in the development, manufacture and marketing of diagnostic tests and analysis systems. The Company operates one business segment, named Diagnostics. The Diagnostics segment offers solutions for the early diagnosis and prevention of gastrointestinal diseases. It provides blood-sample examination based on GastroPanel for the diagnosis of stomach illnesses and associated risks, quick tests for the diagnosis of lactose intolerance and Helicobacter pylori infection in connection with gastroscopy, as well as the ColonView examination for the early detection of fecal occult intestinal bleeding, which indicates a risk of colorectal cancer. The Company's products are used in hospitals, healthcare centers and research institutions. It operates primarily in Europe and Asia. Furthermore, the Company is a parent of Biohit Healthcare Ltd, Biohit Healthcare Srl, Oy Finio Ab, and Vantaan Hienomekano Oy, among others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.96 EUR
Average target price
2.4 EUR
Spread / Average Target
+22.45%
Consensus